Trump announces all 50 states joining Medicaid drug pricing model

All 50 U.S. states will now participate in a federal Medicaid drug pricing program based on Most Favored Nation pricing. The White House projects $64.3 billion in Medicaid savings over ten years ($36.6 billion federal, $27.6 billion state), with 26 major pharmaceutical manufacturers covering 90% of the branded U.S. drug market committed to provide rebates. Agreements with manufacturers and the TrumpRx.gov platform launched in February 2026 have reportedly delivered $700 million in savings to patients; however, limited public disclosure of deal terms prevents independent verification of projected savings, and policy observers note uncertainty about price stability beyond the current administration.